Region- and Subject-Level 18F-Fluciclovine PET/CT BIE Outcomes Compared with Primary SOT
| Region | Reader 1 (n) | Reader 2 (n) | Reader 3 (n) | Overall (n) | Onsite read (n) |
| Prostate | |||||
| N | 98 | 97 | 96 | 97 | 97 |
| TP | 58 (59.2) | 56 (57.7) | 47 (49.0) | 53 (54.6) | 57 (58.8) |
| FP | 29 (29.6) | 26 (26.8) | 15 (15.6) | 20 (20.6) | 27 (27.8) |
| TN | 10 (10.2) | 12 (12.4) | 24 (25.0) | 19 (19.6) | 12 (12.4) |
| FN | 1 (1.0) | 3 (3.1) | 10 (10.4) | 5 (5.2) | 1 (1.0) |
| PPV | 58/87 (66.7%) | 56/82 (68.3%)* | 47/62 (75.8%)* | 53/73 (72.6%)* | 57/84 (67.9%) |
| NPV | 10/11 (90.9%) | 12/15 (80.0%) | 24/34 (70.6%) | 19/24 (79.2%) | 12/13 (92.3%) |
| Sensitivity | 58/59 (98.3%) | 56/59 (94.9%)* | 47/57 (82.5%)* | 53/58 (91.4%)* | 57/58 (98.3%) |
| Specificity | 10/39 (25.6%) | 12/38 (31.6%) | 24/39 (61.5%) | 19/39 (48.7%) | 12/39 (30.8%) |
| Extraprostatic | |||||
| N | 30 | 30 | 27 | 30 | 29 |
| TP | 26 (86.7) | 27 (90.0) | 23 (85.2) | 24 (80.0) | 27 (93.1) |
| FP | 2 (6.7) | 2 (6.7) | 2 (7.4) | 2 (6.7) | 2 (6.9) |
| TN | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| FN | 2 (6.7) | 1 (3.3) | 2 (7.4) | 4 (13.3) | 0 (0.0) |
| PPV | 26/28 (92.9%)* | 27/29 (93.1%)* | 23/25 (92.0%)* | 24/26 (92.3%)* | 27/29 (93.1%) |
| NPV | – | – | – | – | – |
| Sensitivity | 26/28 (92.9%)* | 27/28 (96.4%)* | 23/25 (92.0%)* | 24/28 (85.7%)* | 27/27 (100.0%) |
| Specificity | – | – | – | – | 0/2 (0.0%) |
| Subject | |||||
| N | 104 | 105 | 99 | 102 | 105 |
| TP | 75 (72.1) | 72 (68.3) | 63 (63.6) | 68 (66.7) | 73 (69.5) |
| FP | 24 (23.1) | 23 (21.9) | 13 (13.1) | 18 (17.6) | 19 (18.1) |
| TN | 5 (4.8) | 7 (6.7) | 15 (15.2) | 10 (9.8) | 12 (11.4) |
| FN | 0 (0.0) | 3 (2.9) | 8 (8.1) | 6 (5.9) | 1 (1.0) |
| PPV | 75/99 (75.8%)* | 72/95 (75.7%)* | 63/76 (82.9%)* | 68/86 (79.1%)* | 73/92 (79.3%) |
| NPV | 5/5 (100.0%) | 7/10 (70.0%) | 15/23 (65.2%) | 10/16 (62.5%) | 12/13 (92.3%) |
| Sensitivity | 75/75 (100.0%)* | 72/75 (96.0%)* | 63/71 (88.7%)* | 68/74 (91.9%)* | 73/74 (98.6%) |
| Specificity | 5/29 (17.2%) | 7/30 (23.3%) | 15/28 (53.6%) | 10/28 (35.7%) | 12/31 (38.7%) |
↵* P < 0.001.
n = number of subjects in region meeting criterion; N = number of subjects in analysis; TP = true positive; FP = false positive; TN = true negative; FN = false negative.